European Medicines Agency updated the page, Clinical Trials Regulation: progress on implementation by adding ‘Key performance indicators (KPIs) to monitor the European clinical trials environment (1 – 30 June 2022, edition 3)‘ document over the What’s New Section on July 29, 2022:
It is the third report posted for the period June 01, 2022, to June 30, 2022, consisting of the metrics for the submitted and authorized clinical trial applications along with the non-authorized clinical trials. The data is reported from the two EU clinical-trial databases (Clinical Trials Information System (CTIS) and European Union Drug Regulating Authorities Clinical Trials (EudraCT)) and it is divided into sponsor type, mono-national or multi-national, clinical trial phase, and therapeutic area. Refer to the previous post for the details on the parameters for which the cumulative data is presented in the KPIs.
This report also includes the Annex I section where the average time from the submission of the initial clinical trial up to the time of the first decision of the Member States Concerned is enlisted.